Retrospective analysis of independent predictors of progression‐free survival in patients with EGFR mutation‐positive advanced non‐small cell lung cancer receiving first‐line osimertinib

BACKGROUND: Clinically measurable factors affecting the progression‐free survival (PFS) of patients receiving osimertinib as first‐line therapy for epidermal growth factor receptor (EGFR) mutation‐positive advanced non‐small cell lung cancer (NSCLC) have not yet been established. METHODS: We retrosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Teranishi, Shuhei, Sugimoto, Chihiro, Nagaoka, Satoshi, Nagayama, Hirokazu, Segawa, Wataru, Miyasaka, Atsushi, Hiro, Shuntaro, Kajita, Yukihito, Maeda, Chihiro, Kobayashi, Nobuaki, Yamamoto, Masaki, Kudo, Makoto, Kaneko, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527177/
https://www.ncbi.nlm.nih.gov/pubmed/36082812
http://dx.doi.org/10.1111/1759-7714.14608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527177/
https://www.ncbi.nlm.nih.gov/pubmed/36082812
http://dx.doi.org/10.1111/1759-7714.14608

Ejemplares similares